1039 related articles for article (PubMed ID: 19861461)
1. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
2. Long-term survival with glioblastoma multiforme.
Krex D; Klink B; Hartmann C; von Deimling A; Pietsch T; Simon M; Sabel M; Steinbach JP; Heese O; Reifenberger G; Weller M; Schackert G;
Brain; 2007 Oct; 130(Pt 10):2596-606. PubMed ID: 17785346
[TBL] [Abstract][Full Text] [Related]
3. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
4. Long-term survivors of glioblastoma: clinical features and molecular analysis.
Sonoda Y; Kumabe T; Watanabe M; Nakazato Y; Inoue T; Kanamori M; Tominaga T
Acta Neurochir (Wien); 2009 Nov; 151(11):1349-58. PubMed ID: 19730774
[TBL] [Abstract][Full Text] [Related]
5. Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
Shamsara J; Sharif S; Afsharnezhad S; Lotfi M; Raziee HR; Ghaffarzadegan K; Moradi A; Rahighi S; Behravan J
Cancer Invest; 2009 Oct; 27(8):825-9. PubMed ID: 19544111
[TBL] [Abstract][Full Text] [Related]
6. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
[TBL] [Abstract][Full Text] [Related]
7. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
8. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ
Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791
[TBL] [Abstract][Full Text] [Related]
9. Genetic analyses for predictors of radiation response in glioblastoma.
Shih HA; Betensky RA; Dorfman MV; Louis DN; Loeffler JS; Batchelor TT
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):704-10. PubMed ID: 15978739
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
11. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
[TBL] [Abstract][Full Text] [Related]
12. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.
Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K
Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213
[TBL] [Abstract][Full Text] [Related]
13. Association between response to primary treatments and MGMT status in glioblastoma.
Franceschi E; Tosoni A; Pozzati E; Brandes AA
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
[TBL] [Abstract][Full Text] [Related]
14. Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
Sasai K; Nodagashira M; Nishihara H; Aoyanagi E; Wang L; Katoh M; Murata J; Ozaki Y; Ito T; Fujimoto S; Kaneko S; Nagashima K; Tanaka S
Am J Surg Pathol; 2008 Aug; 32(8):1220-7. PubMed ID: 18580490
[TBL] [Abstract][Full Text] [Related]
15. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
16. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.
Mikeska T; Bock C; El-Maarri O; Hübner A; Ehrentraut D; Schramm J; Felsberg J; Kahl P; Büttner R; Pietsch T; Waha A
J Mol Diagn; 2007 Jul; 9(3):368-81. PubMed ID: 17591937
[TBL] [Abstract][Full Text] [Related]
17. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer.
Ogino S; Hazra A; Tranah GJ; Kirkner GJ; Kawasaki T; Nosho K; Ohnishi M; Suemoto Y; Meyerhardt JA; Hunter DJ; Fuchs CS
Carcinogenesis; 2007 Sep; 28(9):1985-90. PubMed ID: 17621591
[TBL] [Abstract][Full Text] [Related]
18. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
[TBL] [Abstract][Full Text] [Related]
19. Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue.
Araki Y; Mizoguchi M; Yoshimoto K; Shono T; Amano T; Nakamizo A; Suzuki SO; Iwaki T; Sasaki T
Brain Tumor Pathol; 2011 Feb; 28(1):25-31. PubMed ID: 21249460
[TBL] [Abstract][Full Text] [Related]
20. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]